• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

校正组预后曲线及汇总统计数据。

Corrected group prognostic curves and summary statistics.

作者信息

Chang I M, Gelman R, Pagano M

出版信息

J Chronic Dis. 1982;35(8):669-74. doi: 10.1016/0021-9681(82)90019-4.

DOI:10.1016/0021-9681(82)90019-4
PMID:7096530
Abstract

A method is presented for correcting distribution function estimators for distortions in the joint distribution of covariates in the subsamples receiving different treatments. This form of standardization is useful for depicting multivariate analyses and predicting population behavior. Furthermore, it also proves useful for comparing two trials which differ in patient mix and for adjusting estimates for know imbalances in patient characteristics. Standardization though important, is not often used in clinical trials because of the complexities introduced by multiple covariates. The proposed method overcomes these difficulties in a wide class of analyses.

摘要

本文提出了一种方法,用于校正接受不同治疗的子样本中协变量联合分布的扭曲对分布函数估计量的影响。这种标准化形式对于描述多变量分析和预测总体行为很有用。此外,它还被证明对于比较患者构成不同的两项试验以及针对已知的患者特征不平衡调整估计量很有用。标准化虽然很重要,但由于多个协变量带来的复杂性,在临床试验中并不常用。所提出的方法在广泛的一类分析中克服了这些困难。

相似文献

1
Corrected group prognostic curves and summary statistics.校正组预后曲线及汇总统计数据。
J Chronic Dis. 1982;35(8):669-74. doi: 10.1016/0021-9681(82)90019-4.
2
Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.年轻卵巢癌患者的预后因素:AGO研究组、GINECO和NSGO四项前瞻性III期组间试验的分析
Eur J Cancer. 2016 Oct;66:114-24. doi: 10.1016/j.ejca.2016.07.014. Epub 2016 Aug 23.
3
Survival and prognostic factors in patients with ovarian cancer.卵巢癌患者的生存及预后因素
Obstet Gynecol. 2003 May;101(5 Pt 1):885-91. doi: 10.1016/s0029-7844(03)00123-6.
4
Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.年龄和合并症对老年卵巢癌患者治疗方式、治疗依从性和预后的意义。
Gynecol Oncol. 2012 Nov;127(2):367-74. doi: 10.1016/j.ygyno.2012.07.001. Epub 2012 Jul 16.
5
[The risk for women of various ages to die at some time of uterine or ovarian cancer].[不同年龄段女性在某个时间死于子宫癌或卵巢癌的风险]
Ned Tijdschr Geneeskd. 1982 Jul 17;126(29):1316-9.
6
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience.年龄作为卵巢癌的一个预后因素。妇科肿瘤学组的经验。
Cancer. 1993 Jan 15;71(2 Suppl):606-14. doi: 10.1002/cncr.2820710218.
7
Ovarian carcinoma: a multivariate analysis of prognostic factors.卵巢癌:预后因素的多变量分析
Obstet Gynecol. 1985 Feb;65(2):264-70.
8
[Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].[浆液性卵巢腺癌预后模型的构建与应用]
Zhonghua Fu Chan Ke Za Zhi. 2006 Jul;41(7):459-63.
9
[Ovarian carcinomas at the 2nd University Women's Hospital in Vienna between 1958-1967].1958年至1967年间维也纳第二大学妇女医院的卵巢癌
Arch Gynakol. 1970 Aug 31;209(2):175-201. doi: 10.1007/BF00668183.
10
The use of prognostic factors in clinical trials.临床试验中预后因素的应用。
Cancer. 1986 Jul 15;58(2 Suppl):461-7. doi: 10.1002/1097-0142(19860715)58:2+<461::aid-cncr2820581309>3.0.co;2-l.

引用本文的文献

1
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?CENTRIC EORTC 26071-22072和CORE试验中替莫唑胺化疗用于新诊断的胶质母细胞瘤患者:给药时间重要吗?
Neurooncol Pract. 2025 Jan 17;12(2):291-300. doi: 10.1093/nop/npaf006. eCollection 2025 Apr.
2
Cost-effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial.来自CODIFI2随机对照试验的拭子采样与组织采样用于感染性糖尿病足溃疡的成本效益分析
Diabet Med. 2025 May;42(5):e15492. doi: 10.1111/dme.15492. Epub 2025 Feb 27.
3
Analysis of temporal survival trends: considerations and best practice.
时间生存趋势分析:注意事项与最佳实践
BMC Med Res Methodol. 2025 Feb 22;25(1):51. doi: 10.1186/s12874-025-02505-5.
4
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.接受axi-cabtagene ciloleucel治疗的复发/难治性弥漫性大B细胞淋巴瘤患者静脉到静脉时间的影响
Blood Adv. 2025 Jun 10;9(11):2663-2676. doi: 10.1182/bloodadvances.2024013656.
5
Adjusted curves for clustered survival and competing risks data.聚类生存和竞争风险数据的调整曲线。
Commun Stat Simul Comput. 2025;54(1):120-143. doi: 10.1080/03610918.2023.2245583. Epub 2023 Aug 16.
6
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.对于 2 线或多线既往治疗后复发或难治性大 B 细胞淋巴瘤的老年患者和/或 ECOG 体能状态较差的患者,与化疗免疫治疗相比,axicabtagene ciloleucel 的获益。
Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19.
7
Prognostic nomogram and epidemiological analysis for lung atypical carcinoid: A SEER database and external validation study.肺非典型类癌的预后列线图和流行病学分析:SEER 数据库和外部验证研究。
Cancer Med. 2024 Jan;13(1):e6794. doi: 10.1002/cam4.6794. Epub 2023 Dec 20.
8
Visualizing the (Causal) Effect of a Continuous Variable on a Time-To-Event Outcome.可视化连续变量对事件时间结局的(因果)效应。
Epidemiology. 2023 Sep 1;34(5):652-660. doi: 10.1097/EDE.0000000000001630. Epub 2023 Jun 29.
9
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.标准化生存概率:一种用于报告生存数据回归模型的有用且信息丰富的工具。
Br J Cancer. 2022 Nov;127(10):1808-1815. doi: 10.1038/s41416-022-01949-6. Epub 2022 Sep 1.
10
A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation.一个用于估计有或无左截断的事件时间数据的直接调整生存函数的 SAS 宏。
Bone Marrow Transplant. 2022 Jan;57(1):6-10. doi: 10.1038/s41409-021-01435-2. Epub 2021 Aug 19.